Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
מצבים רפואיים
High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma · Fallopian Tube Cancer · Endometrial Cancer · Non-small Cell Lung Cancer · Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC) · Mesothelioma · Breast Adenocarcinoma · Triple Negative Breast Cancer · Hormone Receptor-positive/Her2 Negative Breast Cancer · Platinum-resistant Ovarian Cancer (PROC) · Platinum Sensitive Ovarian Cancer (PSOC) · Primary Refractory Ovarian Cancer · Uterine Cancer
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
USOR HonorHealth, Phoenix, Arizona, United States
USOR Arizona Oncology Associates, Tucson, Arizona, United States
University of California Los Angeles Medical Center, Los Angeles, California, United States
University of California, San Diego; Moores Cancer Center, San Diego, California, United States
USOR Sansum Clinic, Santa Barbara, California, United States
Providence Medical Foundation, Santa Rosa, California, United States
USOR Florida Cancer Specialists South, Fort Myers, Florida, United States
USOR Florida Cancer Specialists North, St. Petersburg, Florida, United States
USOR Florida Cancer Specialists East, West Palm Beach, Florida, United States
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
University of Kansas Medical Center (KUMC), Westwood, Kansas, United States
USOR Maryland Oncology Hematology, Rockville, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
START Midwest, Grand Rapids, Michigan, United States
USOR Minnesota Oncology Hematology, Maplewood, Minnesota, United States
MD Anderson Cancer Center at Cooper- Two Cooper Plaza, Camden, New Jersey, United States
Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma, United States
USOR Oncology Associates of Oregon, P.C., Eugene, Oregon, United States
Compass Oncology - Rose Quarter, Portland, Oregon, United States
USOR Alliance Cancer Specialist, Doylestown, Pennsylvania, United States
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
Tennessee Oncology, Nashville, Tennessee, United States
USOR Texas Oncology, Abilene, Texas, United States
Texas Oncology - Central / South Texas, Austin, Texas, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
USOR Texas Oncology, Fort Worth, Texas, United States
Texas Oncology - Northeast TX, Tyler, Texas, United States
USOR Texas Oncology Gulf Coast, Woodland, Texas, United States
START Mountain Region, West Valley City, Utah, United States
USOR Virginia Cancer Specialists, Fairfax, Virginia, United States
USOR Virginia Oncology Associates, Norfolk, Virginia, United States
Swedish Cancer Institute, Seattle, Washington, United States
Cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
Hunan Cancer Hospital - Phase 1, Changsha, Hunan, China
Hunan Cancer Hospital - Thoracic Medicine Dept II, Changsha, Hunan, China
Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
Jilin Cancer Hospital, Changchun, Jilin, China
Obstetrics & Gynecology Hospital of Fudan University, Chengdu, Shanghai Municipality, China
Fudan University Shanghai Cancer Center - Gynecologic Oncology, Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center- Phase 1, Shanghai, Shanghai Municipality, China
Shanghai East Hospital, Shanghai, Shanghai Municipality, China
Sichuan Cancer Hospital, Shanghai, Sichuan, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Fujian Cancer Hospital, Fujian, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, China
Second Affiliated Hospital of Zhengzhou University, Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China
Second Hospital of Shanxi Medical University, Shanxi, China
Shanxi Cancer Hospital, Shanxi, China
Liaoning Cancer Hospital & Institute, Shengyang, China
Tianjin Cancer Hospital, Tianjin, China
Fukushima Medical University Hospital, Fukushima, Fukushima, Japan
Gunma Prefectural Cancer Center, Ōta, Gunma, Japan
Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
Hyogo Cancer Center, Akashi, Hyōgo, Japan
Saitama Medical University-International Medical Center, Hidaka, Saitama, Japan
Shizuoka Cancer Center, Nagaizumi-chō, Shizuoka, Japan
Cancer Institute Hospital of JFCR, Koto, Tokyo, Japan
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
Yamagata University Hospital, Yamagata, Yamagata, Japan
מובילי המחקר
Study Official
Study Director
Genmab